following a full submission:
fluticasone furoate / vilanterol (Relvar Ellipta®) is accepted for use within NHS Scotland.
Indication under review: the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
There was no statistically significant difference between fluticasone furoate/vilanterol 92/22 micrograms daily and another inhaled corticosteroid/long acting beta2-agonist combination (ICS/LABA) inhaler for 0 to 24 hour serial weighted mean forced expiratory volume in one second, at 24 weeks.
Some alternative ICS/LABA combination inhalers are available at a lower daily cost.
Download detailed advice268KB (PDF)
Medicine details
- Medicine name:
- fluticasone furoate / vilanterol (Relvar Ellipta®)
- SMC ID:
- 966/14
- Indication:
- For the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 June 2014
In March 2018 the marketing authorisation for fluticasone furoate / vilanterol (Relvar Ellipta) was extended to include use in patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. This change will not be assessed by SMC.